Weiss Multi-Strategy Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,000	Closed	-$255K	–	658
2018 Q1	$255K	Buy	+5,000	New	+$252K	0.01%	494
2017 Q1	–	Sell	-20,000	Closed	-$1.52M	–	612
2016 Q4	$1.41M	Sell	20,000 -1,500	-7%	-$106K	0.07%	250
2016 Q3	$1.52M	Sell	21,500 -370	-2%	-$23.6K	0.09%	244
2016 Q2	$1.07M	Sell	21,870 -3,130	-13%	-$202K	0.08%	259
2016 Q1	$1.58M	Buy	25,000 +10,000	+67%	+$654K	0.07%	293
2015 Q4	$1.68M	Hold	15,000	–	–	0.12%	190
2015 Q3	$1.45M	Sell	15,000 -128,432	-90%	-$14.7M	0.06%	215
2015 Q2	$14.7M	Hold	143,432	–	–	0.58%	41
2015 Q1	$8.91M	Buy	143,432 +2,000	+1%	+$111K	0.4%	69
2014 Q4	$6.21M	Hold	141,432	–	–	0.21%	102
2014 Q3	$8.01M	Buy	141,432 +62,232	+79%	+$3.13M	0.2%	138
2014 Q2	$3.56M	Buy	79,200 +3,850	+5%	+$159K	0.08%	261
2014 Q1	$3.68M	Buy	+75,350	New	+$3.88M	0.07%	267

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Weiss Multi-Strategy Advisers's RARE Position: Q2 2018 in Review

Weiss Multi-Strategy Advisers sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2018, closing a stake of 5,000 shares — an estimated $255K sold.

Weiss Multi-Strategy Advisers first reported a position in RARE in Q1 2014 and held it in 13 quarters. The position peaked at $14.7M in Q2 2015. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2018.

Weiss Multi-Strategy Advisers reported no remaining Ultragenyx Pharmaceutical position as of Q2 2018 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 5,000 Ultragenyx Pharmaceutical shares in Q2 2018, an estimated $255K.
Weiss Multi-Strategy Advisers first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 13 quarters.
Weiss Multi-Strategy Advisers's Ultragenyx Pharmaceutical position peaked at $14.7M in Q2 2015.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2018.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2018, filed 14 Aug 2018.